+

WO1996012019A3 - Her4 human receptor tyrosine kinase or the epidermal growth factor receptor family - Google Patents

Her4 human receptor tyrosine kinase or the epidermal growth factor receptor family Download PDF

Info

Publication number
WO1996012019A3
WO1996012019A3 PCT/US1995/013524 US9513524W WO9612019A3 WO 1996012019 A3 WO1996012019 A3 WO 1996012019A3 US 9513524 W US9513524 W US 9513524W WO 9612019 A3 WO9612019 A3 WO 9612019A3
Authority
WO
WIPO (PCT)
Prior art keywords
her4
growth factor
tyrosine kinase
epidermal growth
factor receptor
Prior art date
Application number
PCT/US1995/013524
Other languages
French (fr)
Other versions
WO1996012019A9 (en
WO1996012019A2 (en
Inventor
Gregory D Plowman
Mohammed Shoyab
Clay Siegall
Jean-Michel Culouscou
Ingegerd Hellstrom
Karl E Hellstrom
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to FI971532A priority Critical patent/FI971532L/en
Priority to MX9702664A priority patent/MX9702664A/en
Priority to JP8513469A priority patent/JPH10507362A/en
Priority to AU39632/95A priority patent/AU3963295A/en
Priority to EP95937555A priority patent/EP0787187A1/en
Publication of WO1996012019A2 publication Critical patent/WO1996012019A2/en
Publication of WO1996012019A9 publication Critical patent/WO1996012019A9/en
Publication of WO1996012019A3 publication Critical patent/WO1996012019A3/en
Priority to NO971686A priority patent/NO971686L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The molecular cloning, expression, and biological characteristics of a novel receptor tyrosine kinase related to the epidermal growth factor receptor, termed HER4/p180?erbB4¿, are described. An HER4 ligand capable of inducing cellular differentiation of breast cancer cells is also disclosed. In view of the expression of HER4 in several human cancers and in certain tissues of neuronal and muscular origin, various diagnostic and therapeutic uses of HER4-derived and HER4-related biological compositions are provided.
PCT/US1995/013524 1994-10-14 1995-10-10 Her4 human receptor tyrosine kinase or the epidermal growth factor receptor family WO1996012019A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FI971532A FI971532L (en) 1994-10-14 1995-10-10 HER4, a human receptor tyrosine kinase, which belongs to the group of dermal growth factor receptors
MX9702664A MX9702664A (en) 1994-10-14 1995-10-10 TYROSINE KINASE HUMAN RECEPTOR, HER4 OF THE EPIDERMIC GROWTH FACTOR RECEPTOR FAMILY.
JP8513469A JPH10507362A (en) 1994-10-14 1995-10-10 HER4 human receptor tyrosine kinase
AU39632/95A AU3963295A (en) 1994-10-14 1995-10-10 Her4 human receptor tyrosine kinase
EP95937555A EP0787187A1 (en) 1994-10-14 1995-10-10 Her4 human receptor tyrosine kinase
NO971686A NO971686L (en) 1994-10-14 1997-04-11 HER4-humanreseptortyrosinkinase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32344294A 1994-10-14 1994-10-14
US08/323,442 1994-10-14

Publications (3)

Publication Number Publication Date
WO1996012019A2 WO1996012019A2 (en) 1996-04-25
WO1996012019A9 WO1996012019A9 (en) 1996-07-11
WO1996012019A3 true WO1996012019A3 (en) 1996-08-15

Family

ID=23259216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/013524 WO1996012019A2 (en) 1994-10-14 1995-10-10 Her4 human receptor tyrosine kinase or the epidermal growth factor receptor family

Country Status (9)

Country Link
EP (1) EP0787187A1 (en)
JP (1) JPH10507362A (en)
AU (1) AU3963295A (en)
CA (1) CA2202533A1 (en)
FI (1) FI971532L (en)
IL (1) IL115642A0 (en)
MX (1) MX9702664A (en)
NO (1) NO971686L (en)
WO (1) WO1996012019A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9805398A (en) * 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
US6566104B1 (en) * 1997-10-31 2003-05-20 Georgetown University ERbB-4 targeted ribozymes
JP2006517109A (en) 2003-02-07 2006-07-20 プロテイン デザイン ラブス インコーポレイテッド Amphiregulin antibodies and their use to treat cancer and psoriasis
EP2352851A1 (en) 2008-11-12 2011-08-10 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Use of erbb4 as a prognostic and therapeutic marker for melanoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0599274A1 (en) * 1992-11-24 1994-06-01 Bristol-Myers Squibb Company HER4, a human receptor tyrosine kinase of the epidermal growth factor receptor family

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0599274A1 (en) * 1992-11-24 1994-06-01 Bristol-Myers Squibb Company HER4, a human receptor tyrosine kinase of the epidermal growth factor receptor family

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CULOUSCOU ET AL.: "Characterization of a breast cancer cell differentiation factor that specifically activates the HER4/p180erbB4 receptor", J. BIOL. CHEM., vol. 268, no. 25, 5 September 1993 (1993-09-05), pages 18407 - 18410, XP002004423 *
JESCHKE ET AL.: "Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins", INT. J. CANCER, vol. 60, no. 5, 3 March 1995 (1995-03-03), pages 730 - 739, XP000571537 *
KIHARA ET AL.: "Cytotoxic activity of chimeric toxins containg the epidermal growth factor-like domain of heregulins fused to PE38KDEL, a truncated recombinant form of Pseudomonas exotoxin", CANCER RES., vol. 55, 1 January 1995 (1995-01-01), pages 71 - 77, XP002004425 *
NAGATA ET AL.: "Solution structure of the epidermal growth factor-like domain of heregulin-alpha, a ligand for p180erbB-4", EMBO J., vol. 13, no. 15, 1 August 1994 (1994-08-01), pages 3517 - 3523, XP002004422 *
PLOWMAN ET AL.: "Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family", PROC. NATL ACAD. SCI., vol. 90, March 1993 (1993-03-01), pages 1746 - 1750, XP002004419 *
SIEGAL, ET AL.: "HER4 expression correlates with cytotoxicity directed by a hergulin-toxin fusion protein", J. BIOL. CHEM., vol. 270, no. 13, 31 March 1995 (1995-03-31), pages 7623 - 7630, XP002004424 *
SIEGALL ET AL.: "Activity of HER4 targeted ligand-toxin fusion proteins against human tumors", PROC. AM. ASSOC. CANCER RES. ANN. MEET., vol. 35, March 1994 (1994-03-01), pages 382, XP002004420 *
TZAHAR ET AL.: "ErbB-3 and ErbB-4 function as the respective low and high affinity recpetors of all Neu differentiation factor/heregulin isoforms", J. BIOL. CHEM., vol. 269, no. 40, 7 October 1994 (1994-10-07), pages 25226 - 25233, XP002004421 *

Also Published As

Publication number Publication date
NO971686D0 (en) 1997-04-11
FI971532A7 (en) 1997-06-11
NO971686L (en) 1997-06-16
MX9702664A (en) 1997-06-28
FI971532A0 (en) 1997-04-11
EP0787187A1 (en) 1997-08-06
FI971532L (en) 1997-06-11
CA2202533A1 (en) 1996-04-25
AU3963295A (en) 1996-05-06
IL115642A0 (en) 1996-01-19
WO1996012019A2 (en) 1996-04-25
JPH10507362A (en) 1998-07-21

Similar Documents

Publication Publication Date Title
MX9307317A (en) RECEIVING THYROSINE KINASE, RELATED TO THE HUMAN EPIDERMIC GROWTH FACTOR.
TR199800012T1 (en) Pyrolopyrimidines and applications for preparation.
EP2289940A3 (en) Treatment of metastatic disease
WO1997029779A3 (en) EGF-Genistein conjugates for the treatment of cancer
CA2223016A1 (en) Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of her-2 autophosphorylation properties
EP1992695A3 (en) C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
DE3860043D1 (en) USE OF TREATMENT EXTRACT FOR THE PRODUCTION OF MEDICAL AND COSMETIC PREPARATIONS.
EP0853121A3 (en) Human DNase
CA2389411A1 (en) Use of egfr tyrosine kinase inhibitor for preventing breast cancer
CA2223433A1 (en) Ob protein compositions and methods
EP1535929A3 (en) Megakaryocyte stimulating factors
CA2373794A1 (en) Compositions and uses of et743 for treating cancer
NO971341D0 (en) Promoter for receptor tyrosine kinase TIE
IL84211A0 (en) Tissue derived tumor growth inhibitors,methods of preparation and uses thereof
WO1996012019A3 (en) Her4 human receptor tyrosine kinase or the epidermal growth factor receptor family
WO1999033979A3 (en) Bone marrow secreted proteins and polynucleotides
GR3006236T3 (en)
EP0821969A3 (en) Medicinal Composition comprising TCF-II
AU4324089A (en) Peptide antagonists for use in cancer therapy, and the use of mas oncogene and its product
AU617330B2 (en) Human papillomavirus type 41, its DNA and the proteins encoded therefrom
AU6877587A (en) Expellants of phytopathogenic microbes
AU629423B2 (en) Treatment of multi-drug resistant tumors with quinolyloxazole-2-ones
AU7111587A (en) Perhydrothiazepine and perhydroazepine derivatives,their preparation and their therapeutic use
CA2121358A1 (en) Thymidine phosphorylase for use in the modulation of cellular proliferation or chemotaxis
AU5448490A (en) Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI JP MX NO

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1-159,DESCRIPTION,AND PAGES 160-168,CLAIMS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;PAGES 1/33-33/33,DRAWINGS,REPLACED BY NEW PAGES 1/44-44/44;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI JP MX NO

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2202533

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2202533

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/002664

Country of ref document: MX

Ref document number: 971532

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1995937555

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995937555

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995937555

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载